Home › All Companies › ATOS › Insider Trading

ATOSSA THERAPEUTICS, INC. (ATOS) — Insider Trading

AI-Powered SEC Filing Analysis

← All ATOS filings
Latest Insider Trading Filed: 2026-03-31

Key Insights

  • The reporting person, Steven C. Quay, who is the President and CEO of Atossa Therapeutics, Inc. (ATOS), acquired 65,000 shares of the company's common stock through a grant of restricted stock units (RSUs).
  • The number of securities reported has been adjusted to reflect a 1-for-15 reverse stock split that the company recently effected.
  • Quay also holds an indirect beneficial ownership of 1,483 shares of the company's common stock through his ownership of Ensisheim Partners, LLC.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-31. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-22
  • The CEO of Atossa Therapeutics, Inc. (ATOS) acquired a significant number of 325,203 shares of the company's common stock, indicating their confidence in the company's future prospects.
  • The CEO was also granted 950,000 stock options with an exercise price of $0.603, suggesting potential upside for the company's share price.
  • The CEO holds a significant ownership stake in the company, both directly and indirectly through their ownership in Ensisheim Partners, LLC, aligning their interests with those of other shareholders.
Sentiment: Positive Significance: 7/10
View Original Filing →

Other reports for ATOSSA THERAPEUTICS, INC.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.